Nexstim Receives FDA Clearance for nTMS Therapy for Major Depression
Summary
Nexstim announced that it has received FDA clearance for its navigated transcranial magnetic stimulation therapy for major depressive disorder. The system uses MRI-based neuronavigation to precisely target TMS stimulation to individual patient anatomy. Nexstim's approach aims to improve TMS precision and effectiveness through personalized targeting.
Why it matters
Navigated TMS represents an advancement over conventional TMS by using individual brain imaging to optimize stimulation targeting. Precision targeting could improve response rates and reduce variability in TMS outcomes for depression. FDA clearance enables Nexstim to commercialize its system in the United States, adding to the growing options for non-invasive neurostimulation in psychiatry.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial